HK1225395A1 - 用於治療癌症和病毒感染的免疫受體調節 - Google Patents
用於治療癌症和病毒感染的免疫受體調節Info
- Publication number
- HK1225395A1 HK1225395A1 HK16113672A HK16113672A HK1225395A1 HK 1225395 A1 HK1225395 A1 HK 1225395A1 HK 16113672 A HK16113672 A HK 16113672A HK 16113672 A HK16113672 A HK 16113672A HK 1225395 A1 HK1225395 A1 HK 1225395A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treating cancer
- viral infections
- immunoreceptor
- modulation
- immunoreceptor modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013903189A AU2013903189A0 (en) | 2013-08-22 | Immunomodulator |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1225395A1 true HK1225395A1 (zh) | 2017-09-08 |
Family
ID=52482821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16113672A HK1225395A1 (zh) | 2013-08-22 | 2016-12-01 | 用於治療癌症和病毒感染的免疫受體調節 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160200814A1 (zh) |
EP (1) | EP3036255A4 (zh) |
JP (1) | JP2016530267A (zh) |
KR (1) | KR20160055818A (zh) |
CN (1) | CN105636983A (zh) |
AU (1) | AU2013398294A1 (zh) |
BR (1) | BR112016003528A8 (zh) |
CA (1) | CA2921772A1 (zh) |
HK (1) | HK1225395A1 (zh) |
MX (1) | MX2016002265A (zh) |
SG (1) | SG11201601285XA (zh) |
WO (1) | WO2015024042A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3081576T (pt) | 2013-12-12 | 2019-10-15 | Jiangsu Hengrui Medicine Co | Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo |
US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
PT3303394T (pt) | 2015-05-29 | 2020-07-01 | Ludwig Inst For Cancer Res Ltd | Anticorpos anti-ctla-4 e métodos de uso dos mesmos |
RU2756236C2 (ru) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
AU2017373944B2 (en) | 2016-12-07 | 2022-02-03 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
KR102528384B1 (ko) * | 2017-01-06 | 2023-05-02 | 이뮤너티바이오, 인크. | 감소된 cd96/tigit 발현을 갖는 유전자 변형된 nk-92 세포 |
KR20200073203A (ko) * | 2017-08-11 | 2020-06-23 | 블링크 바이오메디컬 에스아에스 | 면역조절인자로서의 cd96-결합제 |
US20200347130A1 (en) | 2017-11-10 | 2020-11-05 | Jiangsu Hengrui Medicine Co., Ltd. | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof |
AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
CN114729049A (zh) * | 2019-09-27 | 2022-07-08 | 葛兰素史密斯克莱知识产权发展有限公司 | 抗原结合蛋白 |
JPWO2021085295A1 (zh) * | 2019-10-30 | 2021-05-06 | ||
CN116377061B (zh) * | 2022-11-28 | 2024-01-16 | 中山大学孙逸仙纪念医院 | 乳腺癌新辅助化疗耐药标志物及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1777622A (zh) * | 2003-02-24 | 2006-05-24 | 施里昂药品股份公司 | 脊髓灰质炎病毒受体功能的调节 |
EP1481993A1 (en) * | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
WO2005107799A1 (ja) * | 2004-05-06 | 2005-11-17 | Eisai R & D Management Co., Ltd. | 抗Necl-5抗体を有効成分として含む癌治療剤 |
US7767410B2 (en) * | 2006-12-07 | 2010-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
HUE036780T2 (hu) * | 2008-04-09 | 2018-07-30 | Genentech Inc | Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére |
US9149544B2 (en) * | 2009-11-06 | 2015-10-06 | The Penn State Research Foundation | Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo |
CN102204901A (zh) * | 2010-03-30 | 2011-10-05 | 中国科学院上海生命科学研究院 | 调节免疫分子的试剂和方法 |
SG11201601283PA (en) * | 2013-08-22 | 2016-03-30 | Queensland Inst Med Res | Immunoreceptor modulation for treating cancer and viral infections |
-
2013
- 2013-10-03 US US14/913,347 patent/US20160200814A1/en not_active Abandoned
- 2013-10-03 EP EP13891700.0A patent/EP3036255A4/en not_active Withdrawn
- 2013-10-03 WO PCT/AU2013/001132 patent/WO2015024042A1/en active Application Filing
- 2013-10-03 MX MX2016002265A patent/MX2016002265A/es unknown
- 2013-10-03 SG SG11201601285XA patent/SG11201601285XA/en unknown
- 2013-10-03 CA CA2921772A patent/CA2921772A1/en not_active Abandoned
- 2013-10-03 BR BR112016003528A patent/BR112016003528A8/pt not_active IP Right Cessation
- 2013-10-03 JP JP2016535268A patent/JP2016530267A/ja active Pending
- 2013-10-03 AU AU2013398294A patent/AU2013398294A1/en not_active Abandoned
- 2013-10-03 KR KR1020167007431A patent/KR20160055818A/ko not_active Application Discontinuation
- 2013-10-03 CN CN201380079711.6A patent/CN105636983A/zh active Pending
-
2016
- 2016-12-01 HK HK16113672A patent/HK1225395A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160055818A (ko) | 2016-05-18 |
EP3036255A1 (en) | 2016-06-29 |
WO2015024042A1 (en) | 2015-02-26 |
CA2921772A1 (en) | 2015-02-26 |
AU2013398294A1 (en) | 2016-03-17 |
JP2016530267A (ja) | 2016-09-29 |
SG11201601285XA (en) | 2016-03-30 |
BR112016003528A8 (pt) | 2018-01-30 |
CN105636983A (zh) | 2016-06-01 |
EP3036255A4 (en) | 2017-03-22 |
MX2016002265A (es) | 2016-12-16 |
US20160200814A1 (en) | 2016-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225396A1 (zh) | 用於治療癌症和病毒感染的免疫受體調節 | |
HK1225395A1 (zh) | 用於治療癌症和病毒感染的免疫受體調節 | |
ZA201603548B (en) | Anti-cd33 antibodies and immunoconjugates | |
IL245731A0 (en) | Combined treatment for cancer | |
IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
HK1220155A1 (zh) | 治療癌症的方法 | |
EP2968343A4 (en) | POLY THERAPY FOR TREATING CANCER | |
DK3046583T3 (da) | Viruslignende partikelkonjugater til behandling af tumorer | |
SG11201603050TA (en) | Methods for treating cancers | |
IL244353A0 (en) | Compounds and use for cancer treatment | |
HK1213817A1 (zh) | 治療癌症的方法 | |
IL245037A0 (en) | Treatment for pancreatic cancer | |
EP3060216A4 (en) | Methods for treating hcv | |
HK1219513A1 (zh) | 治療癌症的方法 | |
HK1223547A1 (zh) | 癌症治療方法 | |
LT3016682T (lt) | Vėžio gydymo būdai | |
PL3071192T3 (pl) | Związek kurkufenol do zastosowania w leczeniu nowotworu | |
PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
EP3013332A4 (en) | Cancer treatment | |
EP2971044A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
GB201311984D0 (en) | Methods and compounds for preventing or treating osteoarthritis | |
AU2014901002A0 (en) | Immunoreceptor modulation for treating cancer and viral infections | |
AU2014900741A0 (en) | Immunoreceptor modulation for treating cancer and viral infections | |
GB201300546D0 (en) | Cancer Treatment | |
GB201319951D0 (en) | Treating Particle |